Kaléo
Richmond, United StatesFounded 2000Industry
Kaléo develops auto-injector products including a nerve-agent antidote under government funding. CBRNE-relevant work is a notable product line according to its website.
What it does
Threats covered
Categories
Profile
Kaléo is a Richmond, Virginia auto-injector company founded in 2000, not 2003 as some listings give, that develops emergency drug and device products. In chemical defence it is developing a next-generation pralidoxime chloride auto-injector for organophosphate and nerve agent poisoning.
More profile
The US Department of Health and Human Services awarded it the programme in 2024, and the company announced a 96.1 million dollar follow-on award from the Biomedical Advanced Research and Development Authority for the pralidoxime auto-injector. DuoDote, the atropine and pralidoxime auto-injector approved in 2006, is a separate product and was not identified as Kaléo's.
Marathon Asset Management announced its acquisition of Kaléo in November 2021, and it remained the owner in 2025 and 2026. The company celebrated 25 years of drug delivery technology.
Ownership
Owned by Marathon Asset Management since its acquisition in late 2021
Parent: Marathon Asset Management
Sources (5)
- https://kaleo.com/kaleo-marks-25-years-advancing-drug-delivery-technology/
- https://kaleo.com/u-s-department-of-health-and-human-services-awards-kaleo-with-contract-to-develop-next-generation-organophosphate-nerve-agent-poisoning-countermeasure/
- https://kaleo.com/kaleo-awarded-96-1-million-barda-contract-to-advance-2-pam-auto-injector-for-u-s-chemical-threat-preparedness/
- https://www.fda.gov/media/108677/download
- https://www.businesswire.com/news/home/20211129005229/en/Marathon-Asset-Management-Announces-Acquisition-of-Kalo
Not verified or not found
- Exact date of the 96.1 million dollar award: appears in a search summary dated October 2026; the award notice was not opened.
- Founding year: 2000 per the company's 25-year anniversary page.
- Proposed 2026 change of control at the parent level: not checked.
Questions
What does Kaléo do?
Kaléo develops auto-injector products including a nerve-agent antidote under government funding. CBRNE-relevant work is a notable product line according to its website.
Where is Kaléo based?
HQ (as found): Richmond. HQ country: US.
Who owns Kaléo?
Owned by Marathon Asset Management since its acquisition in late 2021. Parent: Marathon Asset Management
Profiles are compiled from public sources and sampled-checked, not fully audited. Last verified 17 October 2026. Report a correction